Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07343596 · ClinicalTrials.gov registry record · NA
Study to Identify Biomarkers of Oral Cavity Cancer Response to Neoadjuvant Immunotherapy Prior to Definitive Surgery
A NA study of Oral Cavity Cancer, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07343596 is a NA study of Oral Cavity Cancer that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 20 participants, below the 225-participant average among 12 other Oral Cavity Cancer trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07343596, a NA study of Oral Cavity Cancer, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to study whether researchers can create a patient-specific tumor system, called a culture vessel, in a timely manner and determine if it can predict how someone will respond to a specific therapy. Participants will: * Undergo a research biopsy * Take pembrolizumab per standard of care prior to surgery
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- DEVICE Patient-Specific Culture Vessel
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-03 |
| Est. Completion | 2027-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07343596
The ClinicalTrials.gov registry entry for NCT07343596 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 225-participant average among 12 other Oral Cavity Cancer trials with a reported enrollment target (91% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Oral Cavity Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT07343596 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT07343596 about?
NCT07343596 is a clinical study titled "Study to Identify Biomarkers of Oral Cavity Cancer Response to Neoadjuvant Immunotherapy Prior to Definitive Surgery". The goal of this clinical trial is to study whether researchers can create a patient-specific tumor system, called a culture vessel, in a timely manner and determine if it can predict how someone will respond to a specific therapy. Participants will: * Undergo a research biopsy * Take pembrolizuma...
What is the current status of trial NCT07343596?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2026-03. Estimated completion is 2027-12.
What conditions does trial NCT07343596 study?
This clinical trial studies the following conditions: Oral Cavity Cancer.
What interventions are being tested in trial NCT07343596?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Patient-Specific Culture Vessel (DEVICE).
Who is sponsoring clinical trial NCT07343596?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07343596 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oral Cavity Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy
RECRUITING · NA
-
The ENHANCE Study: Exercise and Nutrition in Head And Neck CancEr Survivors
ACTIVE NOT RECRUITING · NA
-
Impact of Compliance With Fluoride Use on Caries Incidence After Cancer Therapy
COMPLETED · NA
-
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
RECRUITING · Phase 2
-
Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy
RECRUITING
-
Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.